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Abstract
Background: Although lipid lowering agents as statins are used frequently in hyperlipidemic patients as well as 
patients with cardiac disease, they could have major hepatic side effects, the aim of this study is to evaluate the 
safety of statins mainly atorvastatin on liver as estimated by liver aminotransferase assay.
Materials and Methods: Patients with indication of atorvastatin were included the study. As a before and after 
study all the patients underwent serum level measurement of aminotransferases at the beginning and after three 
month of taking the drug.
Results and Conclusion: HMG-COA reductase as atorvastatin should be safe in different doses 20,40 and 80 
mg in patient with hyperlipidemia with and without cardiac disease without significant hepatotoxicity.
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Introduction
There are multiple cardiovascular risk factors that 
among them hypercholestrolemia as well as diabetes 
and hypertension are increasing in many 
populations1. In patients with obesity and metabolic 
syndrome there would be increase in fat deposition in 
the liver producing fatty liver. Non-alcoholic fatty 
liver disease (NAFLD) encompasses a wide spectrum 
of liver injury. Currently, there are no proven 
effective therapies available. Atorvastatin is a new 3-
hydroxy-3-metylglutaryl coenzyme a reductase 
inhibitor that reduces lipid serum levels2. In both 
situations due to increased risk of cardiovascular 
disease and liver damage,lipid lowering agents 
should be prescribed to correct the lipid 
abnormalities. Statins are highly effective in 
lowering serum cholesterol concentrations and 
preventing ischemic heart disease3. Statins, ezetimibe, 
and bile acid-binding resins can be used individually 
or in combination for lowering lowdensity lipoprotein 
cholesterol (LDL-C) levels. Statins are the most potent 
drugs for lowering LDL-C and are well tolerated in 
most patients. Drug induced hepatotoxicity is 
understimated in many parts of the world, and lipid 
lowering agents are among the list of the culprits.Since 
2001, an ALT level of >3 x ULN and a total bilirubin 
level of >2 x ULN has been used in combination to 
define clinically-significant abnormal liver function, 
with confirmation required by additional clinical and 
laboratory data4. P Hence, an isolated elevated level of 
transaminases does not necessarily indicate 
hepatotoxicity, and an increase of 3 x ULN may not be 
a sufficient biochemical criterion of hepatic lesion 
because of the considerable capacity of the liver to 
withstand damage5,6. PConsumption of 3-hydroxy-3-
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methylglutaryl coenzyme A reductase (HMG-CoA) 
inhibitors, known as statins, has been associated with 
elevated transaminase levels but rarely with acute 
hepatitis. Recently, several cases of acute hepatitis 
secondary to atorvastatin therapy have been 
published7-12. They reported a case of a 72-year-old 
man who developed acute cholestatic hepatitis after 
reinitiatingtreatment with atorvastatin at a higher 
dose than that previously prescribed. After treatment 
discontinuation, the patient made a full recovery, 
with normalization of clinical and laboratory 
findings13. The aim of this study was to evaluate any 
possible injury to the liver by using HMG CO-A 
reductase inhibitors as determined by biochemical 
measurement.
Methods
We conducted the study in 250 patients with 
hypercholestrolemia and cardiac disease in 
cardiology ward or clinic of Modarres hospital. All 
the patients with clear indication for HMG-COA 
reductase took atorvastatin and after three months the 
level of aminotransferases were measured. Patients 
with history of alcohol use,known liver diseases, like 
hepatitis,decompensated heart failure or 
hemodynamic instability, taking medications with the 
elevation of liver enzymes as their side effects like 
valproate, were excluded. We also excluded patients 
with prior elevated liver enzymes, but giving another 
class of lipid lowering agent due to ethical 
consderation. It was a before and after study that the 
serum level of transaminases were measured both 
before and after taking atorvastatin. 
Statistical Analysis
All analysis were performed by SPSS version 
sixteen.
We used student t–test for evaluating the relationship 
among quantitative variables of the study and Chi2 
square of qualitative ones.
Results
The incidence of increased aminotransferase level in 
patients on atorvastatin was 18 percent. It was 3.6 and 
10 percent respectively in our patients taking 20, 40 
and 80 mg of atorvastatin.  Ten patients from all of 
250 patients (4%) had more than 3 times increase in 
liver transferases that the medication was 
discontinued. Two  percent for patients taking less 
than 80 mg atorvastatin and 5 percent of patients on 80 
mg  of the drug had more than 3 times elevation in 
aminotransferase level but the difference was not 
statistically significant (p=0.4). Age distribution of the 
patients  was between 40 to 80 years old in 86.6%. 
Age and sex had no impact on atorvastatin induced 
elevation of transaminases.
Discussion
The 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors or statins are potent inhibitors of 
cholesterol biosynthesis.The overall clinical benefits 
observed with statin therapy appear to be greater than 
what might be expected from changes in lipid profile 
alone, suggesting that the beneficial effects of statins 
may extend beyond their effects on serum cholesterol 
levels14. Bader et al.  described the significance of 
statins in treatment of hyperlipidemic patients  and 
they found that elevated aminotransferases with statins 
was dose dependent a base line LFT may be done 
before starting statins and that is even not necessary 
for asymptomatic patients without a history of liver 
disease using lovastatin15. However, these guidelines 
may seem to be optional as there is no evidence that 
monitoring reduces the rate of hepatotoxicity16-23.
Chalasani et al. retrospectively evaluated the 
hepatotoxicity risk in subjects treated for at least 6 
months with atorvastatin,simvastatin or fluvastatin. 
Drawn from the pharmacological registry of an 
insurance company, the subjects were segregated into 
two groups: one group with elevated transaminases 
before treatment (cohort I; n=342) and another group 
with normal levels of transaminases (cohort II; 
n=1435)24-32. 
The frequency of elevated aminotransferase is <1% for 
low-to-moderated doses (40mg) and reaches 3% for 
high doses (80 mg). Therefore, the risk of suffering 
Figure 1. The frequencies of patients with different cardiac
disease taking Atrovastatin
Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study                                                Talaie et al.
NBM 101 Novelty in Biomedicine 2015, 3, 99-102
from liver failure as a consequence of this class of 
drugs, is low i.e. approximately about 1 per million,
according to notification to regulatory authorities 33.
In a meta-analysis of randomized clinical trials 
(RCTs) of fluvastatin, pravastatin, lovastatin and 
simvastatin at low or moderate doses (<40 mg oral), 
the prevalence of elevated transaminases >3 x ULN 
was similar in the active treatment groups compared 
to the placebo groups, but only slightly higher in two 
studies of fluvastatin versus placebo (1.13% vs.
0.39%, p=0.04)35. However, atorvastatin despite 
being the mostprescribed statin had not been 
included in this meta-analysis. When analyzing 
large-scale RCTs where high-dose atorvastatin was 
used (80 mg oral), the prevalence of asymptomatic 
elevations of transaminases >3 x ULN was slightly 
higher (3%) compared to placebo, or with another 
statin at moderate dose. Statin use is associated with 
a significant reduction in the risk of HCC among 
patients with diabetes. Patients with hepatitis c as 
well as autoimmune hepatitis may be confounding 
for liver aminotransferase level evaluation, so 
excluded from the study.
In this trial we also exclude patients with baseline 
elevation of aminotransferase level but Vuppalanchi 
et al, showed that significant hepatotoxicity from 
lovastatin was very infrequent in this study, and 
individuals with elevated baseline liver enzyme 
levels did not have higher frequency of lovastatin 
hepatotoxicity than those with normal liver enzyme 
levels. Lucena et al. showed that neither old age nor 
female sex had now influence on severity of drug 
induced liver injury as our study .Cohen et al showed 
that there is no evidence that statin therapy should be 
altered or discontinued solely on the basis of elevated 
aminotransferase levels in an asymptomatic patient. 
Should more objective evidence of hepatic 
dysfunction be identified, such as hepatomegaly, 
clinical evidence of jaundice,elevated direct 
bilirubin, or increased prothrombin time, 
discontinuation of statin therapy ought to be 
considered. Our study again showed that atorvastatin 
use in patients with cardiac disease would be safe 
and in comparison to literature reviews,
aminotransferase elevation to more than 3 times 
occurred in 4 percent of our patients. In conclusion 
this study showed that use of statins at high dose in 
patients with cardiac disease would be safe.
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